Stay updated on Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial
Sign up to get notified when there's something new on the Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial page.

Latest updates to the Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study page displays details for a Phase 2 trial of anlotinib for advanced gastrointestinal stromal tumors after imatinib failure, including its eligibility criteria, progression-free-survival outcome, and recruiting site in Beijing, China.SummaryDifference41%

- Check17 days agoChange DetectedThe site footer’s revision label changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner announces NIH website updates and says federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2; the page otherwise remains a 403 Forbidden error page.SummaryDifference0.2%

- Check38 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error with a minimal header and a Home link, replacing the study content and indicating that access to the record is blocked.SummaryDifference17%

Stay in the know with updates to Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anlotinib in Advanced Gastrointestinal Stromal Tumor Clinical Trial page.